Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Julphar
Daiichi Sankyo
Covington
Colorcon
Farmers Insurance
Argus Health
Fuji
Deloitte

Generated: February 25, 2018

DrugPatentWatch Database Preview

Eluxadoline - Generic Drug Details

« Back to Dashboard

What are the generic sources for eluxadoline and what is the scope of eluxadoline patent protection?

Eluxadoline
is the generic ingredient in one branded drug marketed by Allergan Holdings and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eluxadoline has one hundred and fifteen patent family members in thirty-five countries.

There is one drug master file entry for eluxadoline. One supplier is listed for this compound.
Summary for eluxadoline
International Patents:115
US Patents:12
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Suppliers / Packagers: 1
Bulk Api Vendors: 13
Clinical Trials: 2
Patent Applications: 15
Drug Prices:see low prices
DailyMed Link:eluxadoline at DailyMed
Pharmacology for eluxadoline

US Patents and Regulatory Information for eluxadoline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for eluxadoline

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,206 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid ➤ Sign Up
8,609,865 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid ➤ Sign Up
8,859,604 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for eluxadoline

Supplementary Protection Certificates for eluxadoline

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0170005 00225 Estonia ➤ Sign Up PRODUCT NAME: ELUKSADOLIIN;REG NO/DATE: EU/1/16/1126 21.09.2016
90007-7 Sweden ➤ Sign Up PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REG. NO/DATE: EU/1/16/1126 20160921
2017005 Lithuania ➤ Sign Up PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017000009 Germany ➤ Sign Up PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES ENANTIOMER, DIASTEREOMER, RACEMATE ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
0865 Netherlands ➤ Sign Up PRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921
/2017 Austria ➤ Sign Up PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH ANNEHMBARES ENANTIOMER, DIASTEREOMER, RACEMAT ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 (MITTEILUNG) 20160921
2017000010 Germany ➤ Sign Up PRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017 00008 Denmark ➤ Sign Up PRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
Accenture
US Department of Justice
Chinese Patent Office
Cerilliant
McKesson
Deloitte
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot